Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays
Autor: | George Panayiotakopoulos, Vaia Pliaka, Marianna Politou, Nikolaos Meimetis, Christos Fotis, Charalampos Gogos, Leonidas G. Alexopoulos, Meletios A. Dimopoulos, Nikos Tsolakos, Andreas Mentis, Evangelos Terpos, Ioannis P. Trougakos, Angeliki Minia, Alexandros Spyridonidis, Markos Marangos, Karolina Akinosoglou |
---|---|
Rok vydání: | 2021 |
Předmět: |
Adult
Male 0301 basic medicine Adolescent Epidemiology Science Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Antibodies Viral Sensitivity and Specificity Article Serology Population screening Young Adult 03 medical and health sciences 0302 clinical medicine Antigen Antigen assays Coronavirus Nucleocapsid Proteins Humans Medicine Seroprevalence Serologic Tests Multiplex 030212 general & internal medicine Antigens Aged Immunoassay Multidisciplinary biology medicine.diagnostic_test SARS-CoV-2 business.industry COVID-19 Middle Aged Phosphoproteins Virology Immunoglobulin A 030104 developmental biology Immunoglobulin M Immunoglobulin G Spike Glycoprotein Coronavirus biology.protein Female Antibody business |
Zdroj: | Scientific Reports Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021) |
ISSN: | 2045-2322 |
Popis: | There is a plethora of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) serological tests based either on nucleocapsid phosphoprotein (N), S1-subunit of spike glycoprotein (S1) or receptor binding domain (RBD). Although these single-antigen based tests demonstrate high clinical performance, there is growing evidence regarding their limitations in epidemiological serosurveys. To address this, we developed a Luminex-based multiplex immunoassay that detects total antibodies (IgG/IgM/IgA) against the N, S1 and RBD antigens and used it to compare antibody responses in 1225 blood donors across Greece. Seroprevalence based on single-antigen readouts was strongly influenced by both the antigen type and cut-off value and ranged widely [0.8% (95% CI 0.4–1.5%)–7.5% (95% CI 6.0–8.9%)]. A multi-antigen approach requiring partial agreement between RBD and N or S1 readouts (RBD&N|S1 rule) was less affected by cut-off selection, resulting in robust seroprevalence estimation [0.6% (95% CI 0.3–1.1%)–1.2% (95% CI 0.7–2.0%)] and accurate identification of seroconverted individuals. |
Databáze: | OpenAIRE |
Externí odkaz: |